If you have been reading about c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-18. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
== Epidemiology == Few studies have examined the prevalence of FECD on a large scale. First assessed in a clinical setting, Fuchs himself estimated the occurrence of dystrophia epithelialis corneae to be one in every 2000 patients; a rate that is likely reflective of those who progress to advanced disease. Cross-sectional studies suggest a relatively higher prevalence of disease in European countries relative to other areas of the world. Fuchs dystrophy rarely affects individuals under 50 years of age.
== Prognosis == Studies of the life expectancy of patients with Alport syndrome are rare, but one 2012 study found that Alport patients receiving renal replacement therapy (dialysis or kidney transplantation) exhibited, on average, better survival compared with matched controls who had other kidney diseases (and who also received renal replacement therapy).
Larter next appeared as Zerelda Mimms in the western comedy American Outlaws. Directed by Les Mayfield and co-starring Irish actor Colin Farrell and Scott Caan, the film was poorly received by critics and at the box office making only $13 million. She also starred in Kevin Smith's Jay and Silent Bob Strike Back. In 2001, Larter appeared on the cover of Maxim magazine and performed in the stage play The Vagina Monologues in Manhattan, New York. In Spring 2002, Larter moved from Los Angeles to New York. "I was too young and impressionable to handle the pressures of L.A." Larter later recalled in an interview: "I'm a woman now. I am no longer the little girl who could be easily influenced (back then)." While in New York City, she made herself available for independent film projects and being in theater. Larter's first project in New York City was to reprise her role as Clear Rivers in the sequel to Final Destination entitled Final Destination 2. In an interview with IGN, Larter said, "When New Line asked me to come back, I thought it was great. They showed me the script and let me have some input, and it was really terrific." The film made $90 million worldwide with a mixed critical reception. In 2004, Larter served as an associate producer of and starred in the thriller Three Way.
Sources: en.wikipedia.org
Stickland fermentation or The Stickland Reaction is the name for a chemical reaction that involves the coupled oxidation and reduction of amino acids to organic acids. The electron donor amino acid is oxidised to a volatile carboxylic acid one carbon atom shorter than the original amino acid. For example, alanine with a three carbon chain is converted to acetate with two carbons. The electron acceptor amino acid is reduced to a volatile carboxylic acid the same length as the original amino acid. For example, glycine with two carbons is converted to acetate. In this way, amino acid fermenting microbes can avoid using hydrogen ions as electron acceptors to produce hydrogen gas. Amino acids can be Stickland acceptors, Stickland donors, or act as both donor and acceptor. Only histidine cannot be fermented by Stickland reactions, and is oxidised. With a typical amino acid mix, there is a 10% shortfall in Stickland acceptors, which results in hydrogen production. Under very low hydrogen partial pressures, increased uncoupled anaerobic oxidation has also been observed. It occurs in proteolytic clostridia such as: C. perfringens, Clostridioides difficile, C. sporogenes, and C. botulinum. Additionally, sarcosine and betaine can act as electron acceptors.
He later co-founded the Trinity Broadcasting Network with Paul and Jan Crouch, but left after a short partnership due to disagreements, eventually establishing his own ministry, PTL (Praise The Lord), and the PTL Satellite Network. Returning to televangelism in 2003, Bakker now hosts The Jim Bakker Show with a focus on apocalyptic themes and survivalist products, while distancing himself from his earlier prosperity gospel teachings. His later years have included controversial claims, such as predicting major events and promoting unproven supplements, which drew legal action and criticism during the COVID-19 pandemic. Bakker has written several books, including I Was Wrong and Time Has Come: How to Prepare Now for Epic Events Ahead.
When in 1863 the Association of Serbian Philology commemorated the death of Cyril a thousand years earlier, its president Dimitrije Matić talked of the creation of an "ethnically pure" Slavonic people, "With God’s help, there should be a whole Slavonic people with purely Slavonic faces and of purely Slavonic character." After World War I the creation of the Kingdom of Yugoslavia, under Serbian royalty of the Karađorđević dynasty, united most Southern Slavic-speaking nations regardless of religion and cultural background. The only ones they did not unite with were the Bulgarians. Still, in the years after the Second World War, there were proposals to incorporate Bulgaria into a Greater Yugoslavia thus uniting all south Slavic-speaking nations into one state. The idea was abandoned after the split between Josip Broz Tito and Joseph Stalin in 1948. This led to some bitter sentiment between the people of Yugoslavia and Bulgaria in the aftermath. At the end of the Second World War, the Partisans' mixed heritage leader Josip Broz Tito became Yugoslav president, and the country become a socialist republic, with the motto of "Brotherhood and Unity" between its various Slavic peoples.
=== Monitoring === Enoxaparin has predictable absorption, bioavailability, and distribution therefore monitoring is not typically done. However, there are instances where monitoring may be beneficial for special populations, for example individuals with kidney insufficiency or those that are obese. In this case, anti-Xa units can be measured and dosing adjusted accordingly.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.